Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q1 2024 · 10-Q
Revenue—
Net Income-$2.27M-$2.27MN/M vs Q1 2023 EPS Diluted-$1.64-$1.64N/M vs Q1 2023 Operating Income-$3,091,000N/M Operating Cash Flow-$4,163,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end